Matrine Alleviates Sepsis-Induced Acute Lung Injury by Reinforcing NQO1/SLC7A11/GPX4-Associated Anti-Ferroptotic Defenses and Attenuating NF-κB-Driven Inflammation Authors: Xue Chen, Min Yuan, Ting Huang, Yuxuan Wang, Zihan Lei, Jingxue Qing, Hailong Gong, Delida Aidebaike, Zhengyu Zhang, Xiaojing Wu Published: 2026 ABSTRACT BackgroundSepsis triggers dysregulated systemic inflammation and multiple-organ dysfunction, with the lungs being particularly susceptible to injury. Sepsis-induced acute respiratory distress syndrome (ARDS) is mainly driven by TLR4/NF-κB-mediated hyperinflammation and alveolar macrophage activation. Matrine, a bioactive alkaloid derived from Sophora flavescens, has been reported to modulate redox homeostasis and ferroptosis-associated lipid peroxidation. However, the target-specific mechanisms underlying its effects on ferroptosis and inflammatory signaling in sepsis-induced acute lung injury (SALI) remain incompletely understood.PurposeThis study aimed to evaluate the therapeutic effects of matrine in a cecal ligation and puncture (CLP)-induced SALI model and to determine whether its protective effects involve reinforcement of NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses and suppression of NF-κB-driven inflammation.MethodsWe analyzed the single-cell RNA-sequencing (scRNA-seq) dataset GSE273924 to characterize CD45-enriched pulmonary immune-cell subsets in sham mice and mice with intratracheal Escherichia coli-induced pneumonia. Network pharmacology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict Kushen (KS)-related targets and pathways associated with SALI. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) of GSE245013 were used to identify candidate targets. Matrine–NQO1 binding and intracellular target engagement were evaluated using molecular docking, molecular dynamics simulations, surface plasmon resonance (SPR), and the cellular thermal shift assay (CETSA). The therapeutic effects of matrine were assessed in mice with CLP-induced SALI and in lipopolysaccharide (LPS)-stimulated MH-S cells. Lung histopathology, inflammatory cytokine production, target protein expression, ferroptosis-associated indicators, and NF-κB activation were evaluated using molecular, biochemical, and histological assays. The functional contribution of NQO1 was further examined using the NQO1 inhibitor ES936.ResultsscRNA-seq analysis of GSE273924 revealed substantial remodeling of the CD45-enriched pulmonary immune-cell landscape in mice with intratracheal E. coli-induced pneumonia, including macrophage transcriptional programs associated with ferroptosis and inflammatory signaling. Integrated network pharmacology and bioinformatics analyses prioritized NQO1 as a candidate target of matrine and identified NF-κB signaling as a potentially relevant pathway. Molecular docking, molecular dynamics simulations, SPR, and CETSA supported matrine–NQO1 binding and intracellular target engagement. Functionally, matrine improved survival, attenuated lung injury, reinforced NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses, and suppressed NF-κB activation in CLP mice. Similar protective effects were observed in LPS-stimulated MH-S cells. ES936 partially attenuated the matrine-mediated improvements in cell viability, redox homeostasis, ferroptosis-associated indicators, and NF-κB p65 phosphorylation, supporting a functional contribution of NQO1 to the protective effects of matrine.ConclusionMatrine alleviates SALI by reinforcing NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses and attenuating NF-κB-driven inflammation. Introduction Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection and remains a major global health challenge.1,2 Among its pulmonary complications, sepsis-induced acute lung injury (SALI), which may progress to acute respiratory distress syndrome (ARDS), is characterized by diffuse inflammatory lung injury, increased pulmonary endothelial and epithelial permeability, pulmonary edema, hypoxemia, and a loss of aerated lung tissue.3 Sepsis-associated pulmonary inflammation involves complex interactions among alveolar and interstitial macrophages, neutrophils, pulmonary endothelial cells, and alveolar epithelial cells. In particular, activated macrophages can amplify inflammatory cytokine production, oxidative stress, endothelial dysfunction, and disruption of the alveolar–capillary barrier.4–6 However, the mechanisms governing macrophage activation and regulated cell-death pathways in SALI remain incompletely understood, thereby limiting the development of effective targeted therapies. Accumulating evidence indicates that ferroptosis contributes functionally to the pathogenesis of SALI rather than merely serving as a secondary marker of oxidative injury. Ferroptosis is a regulated form of cell death characterized by iron-dependent phospholipid peroxidation resulting from disrupted iron homeostasis and impaired antioxidant defenses.7–9 In SALI, dysregulation of GPX4-dependent lipid peroxide detoxification, SLC7A11-mediated cystine uptake, ACSL4-dependent phospholipid remodeling, and mitochondrial redox metabolism may influence the severity of pulmonary inflammation, vascular permeability, and tissue injury.10–12 Accordingly, interventions that preserve or restore anti-ferroptotic defenses have demonstrated protective effects in recent models of CLP- and LPS-induced lung injury. Matrine is a bioactive quinolizidine alkaloid derived from Sophora flavescens, commonly known as Kushen (KS), and possesses anti-inflammatory, antioxidant, and immunomodulatory properties.13,14 Previous studies have demonstrated the protective effects of matrine in liver fibrosis, cardiovascular injury, and neuroinflammation.15–17 Emerging evidence further suggests that matrine can modulate ferroptosis-related processes. In a model of severe acute pancreatitis-induced acute lung injury, matrine was reported to activate the mitochondrial UCP2/SIRT3/PGC-1α signaling pathway, reduce mitochondrial reactive oxygen species (ROS) production, restore GPX4 expression and glutathione levels, and suppress lipid peroxidation, thereby attenuating ferroptosis-associated injury and improving lung histopathology.18 These findings suggest that upstream regulators of redox homeostasis may contribute to the anti-ferroptotic effects of matrine. To systematically investigate the molecular mechanisms underlying the protective effects of matrine against SALI, we integrated single-cell RNA sequencing, network pharmacology, transcriptomic bioinformatics, molecular docking, molecular dynamics simulations, surface plasmon resonance (SPR), the cellular thermal shift assay (CETSA), in vivo and in vitro experiments, and pharmacological inhibition of NQO1. The therapeutic effects of matrine were evaluated in mice with CLP-induced SALI and in LPS-stimulated MH-S cells, whereas its binding to NQO1 and intracellular target engagement were assessed using complementary biophysical and cellular approaches. The NQO1 inhibitor ES936 was subsequently used to examine the functional contribution of NQO1 to the protective effects of matrine. This multilevel strategy provided evidence that matrine reinforces NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses and attenuates NF-κB-driven inflammation, while identifying NQO1 as a functionally relevant candidate target. The overall study workflow is presented in Figure 1. Figure 1Outline Diagram.The diagram presents a comprehensive workflow for identifying core targets. It includes sections for PCA Analysis, DEGs and WGCNA, leading to the identification of DEGs. Screening of common targets is shown with various charts and a Venn diagram. Target identification involves tools like GEO, STRING and Cytoscape. The process continues with scRNA-seq and network construction, leading to common targets and final core targets. Four final core targets are identified: NQO1, LCN2, NOX1 and NOX4. The workflow includes molecular docking, MD, SPR and CETSA. Experimental validation is conducted in LPS-stimulated MH-S cell models and CLP-induced sepsis mouse models, using CCK-8, biochemical assays, ELISA, WB, IF, H&E, Masson, IHC and qPCR. The diagram integrates various analyses and experiments to systematically investigate molecular mechanisms and identify core targets.A comprehensive workflow diagram for identifying core targets using various analyses and experiments. Outline Diagram. Materials and Methods Animals Male C57BL/6 mice aged 6–8 weeks and weighing 20–25 g were obtained from the Hubei Provincial Center for Animal Experimentation. The mice were housed in groups under controlled environmental conditions, including a 12 h light/dark cycle, an ambient temperature of 22 ± 2°C, and a relative humidity of 55 ± 5%. Standard rodent chow and sterilized water were available ad libitum. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Wuhan University (approval No. WDRY2022-K046) and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. For surgical procedures, mice were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally; Sigma, USA), and an adequate depth of anesthesia was confirmed by the absence of the pedal withdrawal reflex. For terminal sample collection, the mice were deeply anesthetized with sodium pentobarbital using the same dose and route of administration. After the absence of the pedal withdrawal reflex had been confirmed, the mice were euthanized by cervical dislocation under deep anesthesia, and the required tissues were immediately collected. CLP-Induced Sepsis, Drug Administration, and Dose Selection Sepsis was induced using the cecal ligation and puncture (CLP) model under anesthesia with sodium pentobarbital (50 mg/kg, intraperitoneally; Sigma, USA). Before surgery, an adequate depth of anesthesia was confirmed by the absence of the pedal withdrawal reflex. A midline laparotomy was performed to expose the cecum, and the distal portion of the cecum was ligated with a 4–0 silk suture. The cecum was then punctured once through both walls using a 21-gauge needle, and a small amount of fecal material was gently extruded through the puncture site to ensure patency. The cecum was subsequently returned to the abdominal cavity, and the abdominal wall was closed in two layers. Fluid resuscitation was provided by the subcutaneous administration of prewarmed sterile saline. Sham-operated mice underwent the same laparotomy and cecal manipulation without ligation or puncture. To evaluate the therapeutic effects of matrine and select an appropriate dose for subsequent experiments, mice subjected to CLP received a single dose of matrine (MAT; C15H24N2O; molecular weight, 248.36 g/mol; purity ≥98.0%; MedChemExpress, HY-N0164) at 50 or 100 mg/kg by oral gavage 2 h after CLP.19 These groups were designated the low-dose matrine group (MAT-L) and high-dose matrine group (MAT-H), respectively. Dexamethasone (DEX; 1 mg/kg) was included as a positive control, and the corresponding vehicle-control mice received an equivalent volume of phosphate-buffered saline (PBS). Dexamethasone was selected as a reference anti-inflammatory and lung-protective agent because of its established use in experimental models of sepsis and acute lung injury.20 At 24 h after CLP, mice were assigned to separate cohorts for BALF collection, lung wet-to-dry weight determination, or lung tissue assessment. BALF was obtained under deep anesthesia before euthanasia, whereas non-lavaged mice were euthanized under deep anesthesia and their lungs were immediately harvested for gravimetric, histopathological, or molecular evaluation. Matrine administration 2 h after CLP was selected to model an early therapeutic intervention,21 whereas the 24 h sampling time point was chosen to evaluate acute SALI-related pathological and molecular alterations,22,23 consistent with previous studies using CLP-induced acute lung injury models. Among the doses tested, 100 mg/kg produced the most consistent improvements in BALF protein concentration, pulmonary edema, and histopathological lung injury without overt signs of toxicity and was therefore selected for subsequent in vivo experiments. Cell Culture and Drug Treatment The murine alveolar macrophage cell line MH-S was obtained from the American Type Culture Collection (ATCC; CRL-2019). For biochemical and immunoblotting analyses, MH-S cells were seeded in 6-well plates at a density of 3×105 cells per well and cultured for 24 h until they reached approximately 80–85% confluence. Before LPS stimulation, the cells were pretreated with matrine (400 μM; MedChemExpress, China) dissolved in sterile PBS for 2 h.24 LPS (1 μg/mL; Sigma-Aldrich, USA) was subsequently added, and the cells were incubated for an additional 24 h.25 Vehicle-control cells received an equivalent volume of PBS under the same conditions. Cell Viability Assay MH-S cells were seeded in 96-well plates at a density of 1×104 cells per well and allowed to adhere for 24 h. After the indicated treatments, 10 μL of Cell Counting Kit-8 (CCK-8) reagent (Solarbio, CA1210, China) was added to each well, and the plates were incubated at 37°C for 2 h. Absorbance was measured at 450 nm using a microplate reader. Cell viability was calculated relative to that of the corresponding vehicle-treated control and expressed as a percentage. Single-Cell RNA-Sequencing Analysis The publicly available single-cell RNA-sequencing (scRNA-seq) dataset GSE273924 was analyzed to characterize immune-cell heterogeneity in murine lung tissue. According to the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) record and the associated publication, the dataset was generated from CD45-enriched pulmonary immune cells isolated from sham mice and mice with intratracheal Escherichia coli-induced pneumonia.26 Therefore, all analyses of cell-type composition were restricted to the CD45-enriched pulmonary immune-cell compartment. Count matrices were imported into Seurat version 5 for preprocessing and downstream analysis. Cells that did not meet the predefined quality-control criteria were excluded. The retained data were subsequently normalized, and highly variable genes were identified. Principal component analysis (PCA) was performed for dimensionality reduction, and batch effects were mitigated using Harmony. After clustering, uniform manifold approximation and projection (UMAP) was used to visualize the cellular landscape. The expression patterns of Slc7a11, Gpx4, Acsl4, and Nqo1 across the identified immune-cell populations were visualized using feature plots based on the same UMAP embedding. To assess transcriptional differences between experimental groups within defined immune-cell subsets, gene counts were aggregated at the sample level using a pseudobulk approach, followed by differential expression analysis with edgeR. Differentially expressed genes (DEGs) were visualized using volcano plots and heatmaps. Identification of Bioactive Constituents and Potential Targets of Kushen A preliminary search of the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; https://old.tcmsp-e.com/tcmsp.php) identified 45 chemical constituents of Kushen (KS) that satisfied the prespecified thresholds of oral bioavailability (OB) ≥30% and drug-likeness (DL) ≥0.18. The pharmacokinetic and drug-likeness properties of these compounds were then reassessed using SwissADME (http://www.swissadme.ch/). Compounds predicted to exhibit high gastrointestinal absorption and to pass at least two drug-likeness filters were included in the subsequent analyses, resulting in the retention of 25 candidate bioactive constituents. Potential targets associated with these compounds were further predicted using SwissTargetPrediction (http://www.swisstargetprediction.ch/) and PharmMapper (https://www.lilab-ecust.cn/pharmmapper/). Identification of Sepsis- and SALI-Related Targets Genes associated with sepsis and SALI were systematically retrieved from four databases: the Therapeutic Target Database (TTD; https://db.idrblab.net/ttd/), Online Mendelian Inheritance in Man (OMIM; https://www.omim.org/), GeneCards (https://www.genecards.org/), and DisGeNET (https://www.disgenet.org/). The target lists obtained from these databases were merged, and duplicate entries were removed to generate a nonredundant set of sepsis- and SALI-related targets for subsequent analyses. Identification of Differentially Expressed Genes The transcriptomic dataset GSE245013 was obtained from the GEO. Of the 20 murine samples included in the dataset, five sham-operated samples and five samples from mice with CLP-induced sepsis were included in the comparative analysis. Differential expression analysis was performed using the limma package through the Sangerbox platform (https://sangerbox.com/home.html). Genes with a false discovery rate (FDR) <0.05 and an absolute log2 fold change (|log2FC|) >1 were considered differentially expressed. Weighted Gene Co-Expression Network Analysis Weighted gene co-expression network analysis was performed using the WGCNA package (version 1.74). After sample and gene quality assessment using goodSamplesGenes, the normalized expression matrix containing 17,980 genes from 10 samples was used for network construction. Candidate soft-thresholding powers from 1 to 30 were evaluated using pickSoftThreshold. A signed scale-free topology fit cutoff of R2 ≥ 0.85 was predefined. A power of β = 10 was retained because it yielded a signed scale-free topology fit index of 0.884 while maintaining a mean connectivity of 1,129.79. An unsigned adjacency network and unsigned topological overlap matrix were constructed using Pearson correlation. Modules were detected using blockwiseModules with a maximum block size of 5,000 genes, minimum module size of 30, deepSplit = 2, and mergeCutHeight = 0.25. Module eigengenes were subsequently correlated with the CLP and sham traits. GO and KEGG Enrichment Analyses Functional enrichment analysis of the overlapping targets was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID; https://david.ncifcrf.gov/). Gene Ontology (GO) enrichment analysis included biological process (BP), cellular component (CC), and molecular function (MF) categories, whereas Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to identify enriched signaling pathways. The enrichment results were visualized using the Bioinformatics Analysis Platform (https://www.bioinformatics.com.cn/) to characterize the biological functions and pathways potentially associated with the effects of KS on SALI. Identification of Core Targets The overlapping targets were uploaded to the STRING database (version 12.0; https://cn.string-db.org/) for protein–protein interaction (PPI) analysis. The resulting PPI network was imported into Cytoscape (version 3.10.1) for visualization and topological analysis. Hub targets were identified using the Molecular Complex Detection (MCODE) plugin and subsequently intersected with ferroptosis-associated genes retrieved from FerrDb, yielding four final core targets. Molecular Docking The three-dimensional structures of the four core targets—NQO1 (PDB ID: 1D4A), NOX4 (AlphaFold DB ID: AF-Q9NPH5-F1), NOX1 (AlphaFold DB ID: AF-Q9Y5S8-F1), and LCN2 (PDB ID: 4MVK)—were obtained from the RCSB Protein Data Bank27 and the AlphaFold Protein Structure Database.28 The protein structures were prepared using PyMOL (version 2.3.0). The three-dimensional structure of matrine, the principal bioactive compound selected for validation, was retrieved from PubChem (CID: 91466) and subjected to energy minimization using the Merck Molecular Force Field 94 (MMFF94) implemented in Open Babel (version 3.1.1). Receptor and ligand files were prepared using AutoDockTools (version 1.5.6), and semi-flexible molecular docking was performed using AutoDock Vina (version 1.2.5). Five independent docking runs were conducted for each matrine–target pair. The predicted binding energies were expressed as the mean ± standard deviation (SD). The estimated inhibition constant (Ki) and negative logarithm of the inhibition constant (pKi) were derived from the predicted binding energy using the equations described below.29 (1)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$\left[{{K_{\mathrm{i}}}\left({\mathrm{M}} \right) = \exp \left({{{{\mathrm{\Delta\ }}G} \over {RT}}} \right), R = 0.001987{\mathrm{kcal}}/\left({{\mathrm{mol}}\cdot{\mathrm{K}}} \right),T = 298{\mathrm{K}}} \right]$$\end{document}(2)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$[{K_{\mathrm{i}}}\left({{\mathrm{\mu\ M}}} \right) = {K_{\mathrm{i}}}\left({\mathrm{M}} \right) \times {10^6} ]{\ }$$\end{document}(3)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$${\ }\left[{{\mathrm{p}}{K_{\mathrm{i}}} = - {{\log }_{10}}\left({{K_{\mathrm{i}}}\left({\mathrm{M}} \right)} \right) } \right]$$\end{document} Molecular Dynamics Simulations Molecular dynamics (MD) simulations were performed for the matrine–NQO1 complex and the apo-NQO1 system using GROMACS version 2024.4. The protein and ligand were parameterized using the AMBER14SB and General Amber Force Field 2 (GAFF2) force fields, respectively. Each system was solvated in a periodic box containing TIP4P water molecules and neutralized by adding Na+ and Cl− ions. Following energy minimization and sequential equilibration, a 100 ns production simulation was conducted with a 2 fs integration time step under periodic boundary conditions. Trajectory analyses included the root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), hydrogen-bond occupancy, and binding free-energy estimation. Representative structures were extracted at 0, 25, 50, 75, and 100 ns to evaluate the temporal evolution and conformational stability of the matrine–NQO1 complex. Surface Plasmon Resonance Surface plasmon resonance (SPR) analysis was performed to determine the binding affinity between matrine and NQO1. An activation solution was freshly prepared by combining 400 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 100 mM N-hydroxysuccinimide (NHS) immediately before use. A CM5 sensor chip was activated with the EDC/NHS solution for 420 s at a flow rate of 10 μL/min. NQO1 was diluted to 20 μg/mL in immobilization buffer and injected over the active flow cell (Fc2) at 10 μL/min, resulting in an immobilization level of approximately 12,600 response units (RU). The reference flow cell (Fc1) underwent the same activation and deactivation procedures without NQO1 immobilization. The remaining activated carboxyl groups were blocked with 1 M ethanolamine hydrochloride for 420 s at 10 μL/min. Matrine was prepared in analyte buffer at seven concentrations ranging from 0.16 to 10 μM and injected over both Fc1 and Fc2 at a flow rate of 20 μL/min. Each injection consisted of a 100 s association phase followed by a 180 s dissociation phase in analyte buffer. Seven injection cycles were performed in ascending order of matrine concentration, and the sensor surface was regenerated after each cycle. Cellular Thermal Shift Assay A cellular thermal shift assay (CETSA) was performed to evaluate the intracellular target engagement of NQO1 by matrine. MH-S cells were treated with matrine (400 μM) or an equivalent volume of PBS (vehicle control) for 2 h and then divided equally into eight aliquots. The aliquots were heated at temperatures ranging from 37°C to 72°C in 5°C increments, with each temperature maintained for 3 min. After heating, the samples were cooled, lysed, and centrifuged to remove thermally precipitated proteins. NQO1 abundance in the soluble protein fractions was determined by immunoblotting. The experiment was performed using five independent biological replicates. Histological Analysis Paraffin-embedded lung sections were mounted on poly-L-lysine-coated slides, deparaffinized in xylene, and rehydrated through a graded ethanol series. For hematoxylin and eosin (H&E) staining, the sections were stained with Mayer’s hematoxylin, differentiated in 0.3% acid alcohol, blued in Scott’s tap water substitute, and counterstained with eosin Y. For Masson’s trichrome staining, the sections were sequentially stained with Weigert’s iron hematoxylin and Biebrich scarlet–acid fuchsin, differentiated in phosphomolybdic–phosphotungstic acid, and counterstained with aniline blue. After dehydration and clearing, the stained sections were mounted with Permount. Histopathological lung injury was evaluated using a standardized scoring system. Elisa The concentrations of IL-1β, IL-6, and TNF-α were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Jianglai Bio, China) according to the manufacturer’s instructions. Reverse Transcription Quantitative PCR Total RNA was extracted from lung tissues using TRIzol reagent (Invitrogen, USA), and complementary DNA (cDNA) was synthesized using a reverse transcription kit (Vazyme, China). Quantitative PCR was performed using a CFX384 Touch Real-Time PCR Detection System (Bio-Rad, USA). Relative mRNA expression was calculated using the 2^−ΔΔCt method, with β-actin as the reference gene. The primer sequences are listed in Table 1.Table 1Quantitative PCR Primer SequencesPrimer NameForward Primer SequenceReverse Primer SequenceTnfGGCATGGATCTCAAAGACAACCCAGGTATATGGGCTCATACCAGIl1bGAAATGCCACCTTTTGACAGTGTGGATGCTCTCATCAGGACAGIl6CATGTTCTCTGGGAAATCGTGGGTACTCCAGGTAGCTATGGTACActbGGCTGTATTCCCCTCCATCGCCAGTTGGTAACAATGCCATGT Table 1Quantitative PCR Primer SequencesPrimer NameForward Primer SequenceReverse Primer SequenceTnfGGCATGGATCTCAAAGACAACCCAGGTATATGGGCTCATACCAGIl1bGAAATGCCACCTTTTGACAGTGTGGATGCTCTCATCAGGACAGIl6CATGTTCTCTGGGAAATCGTGGGTACTCCAGGTAGCTATGGTACActbGGCTGTATTCCCCTCCATCGCCAGTTGGTAACAATGCCATGT Quantitative PCR Primer Sequences Western Blotting Total protein was extracted from lung tissue homogenates and MH-S cell lysates, and protein concentrations in the clarified supernatants were determined using a BCA assay kit (Beyotime, China). Proteins were separated on 10% SDS–PAGE gels (Epizyme, China) and transferred to PVDF membranes. The membranes were blocked with rapid blocking buffer (Epizyme, China) and incubated overnight at 4°C with the indicated primary antibodies. After washing, the membranes were incubated with HRP-conjugated secondary antibodies (1:10,000; ABclonal or Proteintech). Protein bands were detected using an enhanced chemiluminescence substrate (Abbkine, China) and imaged with a ChemiDoc Imaging System (Bio-Rad, USA). Band intensities were quantified using ImageJ software. ACSL4, GPX4, SLC7A11, NQO1, and total NF-κB p65 levels were normalized to β-actin, whereas phosphorylated NF-κB p65 was normalized to total NF-κB p65. The primary antibodies used were as follows: anti-ACSL4 (#22401-1-AP, Proteintech), anti-GPX4 (#67763-1-Ig, Proteintech), anti-SLC7A11 (#26864-1-AP, Proteintech), anti-NQO1 (#67240-1-Ig, Proteintech), anti-phospho-NF-κB p65 (p-NF-κB, Ser536, #TP56372F, Abmart), anti-NF-κB p65 (#T55034F, Abmart), anti-β-actin (#AC026, ABclonal). Immunohistochemical Analysis Paraffin-embedded lung sections were deparaffinized, rehydrated through a graded ethanol series, and subjected to antigen retrieval. The sections were then blocked with 5% bovine serum albumin (BSA) and incubated overnight at 4°C with the following primary antibodies: anti-F4/80 (#29414-1-AP, Proteintech), anti-NQO1 (#67240-1-Ig, Proteintech), and anti-phospho-NF-κB p65 (#PC0982, Abmart). After washing, the sections were incubated with the appropriate species-specific secondary antibodies (1:500; MXB Biotechnologies, China) at room temperature. Immunoreactivity was visualized using 3,3′-diaminobenzidine (DAB), and the nuclei were counterstained with Mayer’s hematoxylin. The stained sections were examined under a light microscope. Immunofluorescence Staining Lung sections were deparaffinized in xylene, rehydrated through a graded ethanol series, and subjected to heat-induced antigen retrieval. After permeabilization with 0.3% Triton X-100, nonspecific binding sites were blocked with 5% BSA at room temperature. The sections were then incubated overnight at 4°C with anti-NQO1 (#67240-1-Ig, Proteintech) and anti-phospho-NF-κB p65 (#PC0982, Abmart) primary antibodies. After washing with PBS, the sections were incubated with appropriate fluorophore-conjugated secondary antibodies and counterstained with DAPI to visualize the nuclei. The sections were mounted using an antifade mounting medium and examined under a fluorescence microscope. Biochemical Assays Lung tissue homogenates and MH-S cell lysates were analyzed using commercially available kits according to the respective manufacturers’ instructions. Reduced glutathione (GSH), malondialdehyde (MDA), and ferrous iron (Fe2+) levels were measured using a Reduced Glutathione Micro-Assay Kit (Nanjing Jiancheng Bioengineering Institute, China), a Lipid Peroxidation MDA Assay Kit (Beyotime, China), and a Total/Ionic Iron Quantification Kit (Beyotime, China), respectively. Pharmacological Inhibition of NQO1 To examine the functional contribution of NQO1 to the protective effects of matrine, MH-S cells were treated with ES936, a mechanism-based NQO1 inhibitor (MedChemExpress, HY-100367). ES936 was dissolved in dimethyl sulfoxide (DMSO) and diluted to the indicated concentrations in complete culture medium. The final concentrations of PBS and DMSO were matched across all experimental groups. To select a non-cytotoxic working concentration, cells were exposed to ES936 at 25, 50, 100, 200, or 500 nM for 24 h, with vehicle-treated cells serving as the control. Cell viability was then evaluated using the CCK-8 assay. Based on the absence of detectable cytotoxicity and previously reported conditions for cellular NQO1 inhibition, 100 nM ES936 was selected for subsequent experiments. This concentration and a 30 min pretreatment period were consistent with previous studies showing that 100 nM ES936 inhibited more than 95% of cellular NQO1 activity within 30 min.30–32 For mechanistic experiments, cells were pretreated with ES936 (100 nM) for 30 min, followed by the addition of matrine (400 μM) for 2 h. LPS (1 μg/mL) was then added without replacing the culture medium, and the cells were incubated for an additional 24 h. ES936 and matrine remained present throughout the period of LPS stimulation. Statistical Analysis Statistical analyses were performed using GraphPad Prism version 10.1.2 (GraphPad Software, USA). Data are presented as the mean ± SD, and n denotes independent biological replicates; technical replicates were not included. Normality and homogeneity of variance were assessed using the Shapiro–Wilk and Levene’s tests, respectively. Two-group comparisons were performed using an unpaired two-tailed Student’s t-test or Mann–Whitney U-test, as appropriate. Comparisons among three or more groups were performed using one-way ANOVA followed by Tukey’s test or the Kruskal–Wallis test followed by Dunn’s test. Survival curves were analyzed using the Kaplan–Meier method and Log rank test. All tests were two-sided, and P < 0.05 was considered statistically significant. Significance was defined as follows: ns, not significant; *P < 0.05, **P < 0.01 and ***P < 0.001. Results Single-Cell RNA Sequencing Reveals Ferroptosis-Associated Programs and Inflammatory Activation in CD45-Enriched Pulmonary Immune Cells To characterize immune-cell composition and transcriptional programs potentially relevant to SALI, we reanalyzed the publicly available scRNA-seq dataset GSE273924. Following stringent quality-control filtering, the distributions of detected gene numbers, unique molecular identifier (UMI) counts, and mitochondrial transcript proportions were within the predefined ranges, supporting the suitability of the retained cells for downstream analyses (Figure S1A). Unsupervised clustering and UMAP identified the major immune-cell populations within the CD45-enriched pulmonary compartment, including neutrophils, macrophages, CD8+ T cells, CD4+ T cells, natural killer cells, and B cells (Figure 2A). Cell-type annotations were further confirmed using the expression patterns of canonical marker genes (Figure 2B). To further examine the cell-type specificity of ferroptosis-associated transcriptional programs during pneumonia, we assessed the single-cell expression patterns of Slc7a11, Gpx4, Acsl4, and Nqo1 across the CD45-enriched pulmonary immune-cell landscape. UMAP feature plots revealed distinct cell-type-dependent and heterogeneous expression patterns for these genes (Figure 2C). Gpx4 was broadly expressed across multiple immune-cell populations, whereas Slc7a11 and Acsl4 showed relatively restricted expression patterns in specific immune-cell populations; Nqo1 expression was predominantly confined to a small subset of cells. Figure 2Single-cell RNA sequencing identifies ferroptosis-associated programs and inflammatory activation in CD45-enriched pulmonary immune cells from GSE273924. (A) UMAP visualization of the major CD45-enriched pulmonary immune-cell populations. (B) Marker genes used for cell-type annotation. (C) UMAP feature plots showing the single-cell expression patterns of Slc7a11, Gpx4, Acsl4, and Nqo1 across the major CD45-enriched pulmonary immune-cell populations. Color intensity indicates the normalized expression level of each gene. (D) Comparison of CD45-enriched pulmonary immune-cell distributions between sham samples (left) and samples from mice with intratracheal E. coli-induced pneumonia (right). (E) Volcano plot showing differential gene expression in macrophages between sham samples and samples from mice with intratracheal E. coli-induced pneumonia. (F) KEGG enrichment analysis of macrophage DEGs. (G) GO biological process enrichment analysis of macrophage pseudobulk data, showing significant enrichment of terms associated with macrophage activation, inflammatory signaling, and ferroptosis-associated processes. Dot size represents the gene count, and dot color represents −log10(P). (H) GSEA of macrophage pseudobulk data showing enrichment of the “response to oxidative stress” gene set.An infographic examines immune-cell changes in pneumonia. Panels A to D at the top show: A) UMAP visualization of major pulmonary immune-cell populations; B) marker genes for cell types; C) gene expression for Slc7a11, Gpx4, Acsl4, Nqo1; D) immune-cell distribution shifts between sham and pneumonia samples. Panels E to H at the bottom include: E) a volcano plot of gene regulation in macrophages; F) KEGG analysis highlighting NF-kappa B and ferroptosis pathways; G) GO enrichment on macrophage activation and ferroptosis; H) GSEA results showing oxidative stress response enrichment. The grid layout aids understanding of pneumonia′s impact on immune cells.Infographic: immune-cell shifts in pneumonia, focusing on macrophages, ferroptosis, oxidative stress. Single-cell RNA sequencing identifies ferroptosis-associated programs and inflammatory activation in CD45-enriched pulmonary immune cells from GSE273924. (A) UMAP visualization of the major CD45-enriched pulmonary immune-cell populations. (B) Marker genes used for cell-type annotation. (C) UMAP feature plots showing the single-cell expression patterns of Slc7a11, Gpx4, Acsl4, and Nqo1 across the major CD45-enriched pulmonary immune-cell populations. Color intensity indicates the normalized expression level of each gene. (D) Comparison of CD45-enriched pulmonary immune-cell distributions between sham samples (left) and samples from mice with intratracheal E. coli-induced pneumonia (right). (E) Volcano plot showing differential gene expression in macrophages between sham samples and samples from mice with intratracheal E. coli-induced pneumonia. (F) KEGG enrichment analysis of macrophage DEGs. (G) GO biological process enrichment analysis of macrophage pseudobulk data, showing significant enrichment of terms associated with macrophage activation, inflammatory signaling, and ferroptosis-associated processes. Dot size represents the gene count, and dot color represents −log10(P). (H) GSEA of macrophage pseudobulk data showing enrichment of the “response to oxidative stress” gene set. Comparison of sham samples with samples from mice with intratracheal Escherichia coli-induced pneumonia revealed marked remodeling of the CD45-enriched pulmonary immune-cell landscape. This remodeling was characterized by increased representation of neutrophils and macrophages, together with redistribution among T-cell and natural killer-cell subsets (Figure 2D). Macrophage-specific pseudobulk differential expression analysis further revealed extensive transcriptional alterations, including the upregulation of numerous inflammation- and metabolism-related genes in the pneumonia-model samples (Figures 2E and S1B). Pathway enrichment analysis identified NF-κB, TNF, Toll-like receptor, and MAPK signaling among the prominently enriched inflammatory pathways, together with significant enrichment of the ferroptosis pathway (Figure 2F). GO biological process analysis further highlighted terms associated with macrophage activation, NF-κB-related regulation, and ferroptosis-associated processes (Figures 2G and S1C). Consistently, gene set enrichment analysis indicated enrichment of gene sets related to oxidative stress responses and ferroptosis (Figures 2H and S1D). Collectively, these findings demonstrate substantial remodeling of the CD45-enriched pulmonary immune-cell compartment in mice with intratracheal E. coli-induced pneumonia, with prominent inflammatory and ferroptosis-associated transcriptional changes, particularly in macrophages. These exploratory findings provided an immune-cell-specific molecular context for subsequent experimental validation in CLP-induced SALI. Network Pharmacology Analysis of Potential Kushen Targets in SALI A total of 45 Kushen (KS)-associated constituents were initially retrieved from the TCMSP database using the predefined criteria of oral bioavailability and drug-likeness. Further screening with SwissADME retained 25 candidate bioactive constituents (Table S1). Target prediction using SwissTargetPrediction and PharmMapper yielded 611 nonredundant protein targets after duplicate entries were removed. In parallel, 3,235 targets associated with sepsis and SALI were compiled from the TTD, OMIM, GeneCards, and DisGeNET databases. Intersection analysis identified 313 common targets shared between the KS-associated and SALI-associated target sets (Figure S2A). These overlapping targets were imported into Cytoscape version 3.10.1 to construct a constituent–target–disease network (Figure S2B). In the network, KS, candidate constituents, SALI, and protein targets were represented by purple, blue, light-coral, and turquoise nodes, respectively. To examine potential protein–protein interactions, the 313 common targets were submitted to the STRING database for network construction (Figure S2C). After four disconnected nodes were removed, the resulting protein–protein interaction network contained 309 nodes and 5,162 edges. Network topology was evaluated using the NetworkAnalyzer tool in Cytoscape. Node size and color intensity were scaled according to centrality values, with larger and more intensely colored nodes indicating potentially greater topological importance within the network (Figure S2D). Functional enrichment analysis of the 313 common targets was performed using the DAVID platform and included GO enrichment across the biological process (BP), cellular component (CC), and molecular function (MF) categories, as well as KEGG pathway enrichment analysis (Figure S2E–F). The enriched GO terms included “inflammatory response,” “response to lipopolysaccharide,” and “protein phosphorylation,” whereas KEGG analysis identified ferroptosis and NF-κB signaling among the significantly enriched pathways. Collectively, these findings suggest that the potential effects of KS on SALI may involve multiple targets and biological processes associated with ferroptosis and inflammatory signaling. Identification of Key Targets Through Integrated Differential Expression and WGCNA Differential expression analysis of the GSE245013 dataset was performed using the limma package, with FDR < 0.05 and |log2FC| > 1 as the significance thresholds. Among the 22,404 genes analyzed, 2,127 were differentially expressed, including 1,037 upregulated and 1,090 downregulated genes. PCA was used to assess the overall variation and distribution of the samples (Figure S3A). The distribution and expression patterns of the differentially expressed genes (DEGs) were visualized using a volcano plot and a hierarchical clustering heatmap, respectively (Figure S3B–C). To further characterize gene co-expression patterns, WGCNA was performed. A soft-thresholding power of β = 10 was selected to approximate scale-free network topology (Figure S3D). Genes were subsequently assigned to distinct co-expression modules (Figure S3E), and the relationships between module eigengenes and the SALI phenotype were evaluated (Figure S3F). Among the identified modules, the darkgrey module exhibited the strongest positive correlation with the SALI phenotype (r = 0.82), whereas the blue module showed the strongest negative correlation (r = −0.97). Intersection of the 2,127 DEGs with the 313 targets shared between the KS-associated and SALI-associated target sets yielded 66 overlapping genes (Figure 3A). These genes were submitted to the STRING database to construct a PPI network, which was subsequently visualized using Cytoscape (Figure 3B and C). GO enrichment analysis identified terms associated with inflammatory and redox-related functions, including “response to lipopolysaccharide,” “inflammatory response,” “NADPH oxidase complex,” and “nuclear receptor activity” (Figure 3D). KEGG pathway analysis further highlighted ferroptosis and NF-κB signaling as key pathways implicated in SALI (Figure 3E). Figure 3Identification of candidate targets and prioritization of ferroptosis-associated targets. (A) Venn diagram showing the intersection between 2,127 DEGs from GSE245013 and 313 targets shared between the KS-associated and SALI-associated target sets, yielding 66 overlapping genes. (B) PPI network of the 66 overlapping genes constructed using the STRING database. (C) Cytoscape visualization of the PPI network. Node size and color intensity represent the degree of each node. (D) GO enrichment analysis of the 66 overlapping genes, classified into BP, CC, and MF categories. (E) KEGG pathway enrichment analysis of the 66 overlapping genes. The color gradient represents enrichment significance, and the red boxes highlight the ferroptosis and NF-κB signaling pathways. (F) MCODE clustering of the PPI network showing three densely connected clusters. The colored boxes and arrows indicate different MCODE clusters; the MCODE scores for Clusters 1, 2, and 3 were 10.235, 4, and 3, respectively. (G) Subnetwork of Cluster 1 highlighting highly connected hub targets. (H) Venn diagram showing the intersection between 18 hub targets from Cluster 1 and 484 ferroptosis-associated genes from FerrDb. The red box highlights the four final ferroptosis-associated core targets: NQO1, NOX4, NOX1, and LCN2.The image A shows a Venn diagram with 313 common targets and 2127 DEGs, intersecting at 66 genes. The image B shows a PPI network of the 66 overlapping genes. The image C shows a Cytoscape visualization of the PPI network, highlighting nodes like TNF and MPO. The image D shows a bar chart of GO enrichment analysis, with categories like biological process, cellular component and molecular function. The image E shows a bar chart of KEGG pathway enrichment analysis, highlighting pathways such as neutrophil extracellular trap formation and NF-kappa B signaling. The image F shows MCODE clustering of the PPI network into three clusters with scores 10.235, 4 and 3. The image G shows a subnetwork of Cluster 1 with hub targets like TNF and MPO. The image H shows a Venn diagram intersecting 18 hub targets from Cluster 1 with 484 ferroptosis-associated genes, highlighting four core targets: NQO1, NOX4, NOX1 and LCN2.Diagrams depict gene intersections, PPI networks, enrichment and clustering of ferroptosis targets. Identification of candidate targets and prioritization of ferroptosis-associated targets. (A) Venn diagram showing the intersection between 2,127 DEGs from GSE245013 and 313 targets shared between the KS-associated and SALI-associated target sets, yielding 66 overlapping genes. (B) PPI network of the 66 overlapping genes constructed using the STRING database. (C) Cytoscape visualization of the PPI network. Node size and color intensity represent the degree of each node. (D) GO enrichment analysis of the 66 overlapping genes, classified into BP, CC, and MF categories. (E) KEGG pathway enrichment analysis of the 66 overlapping genes. The color gradient represents enrichment significance, and the red boxes highlight the ferroptosis and NF-κB signaling pathways. (F) MCODE clustering of the PPI network showing three densely connected clusters. The colored boxes and arrows indicate different MCODE clusters; the MCODE scores for Clusters 1, 2, and 3 were 10.235, 4, and 3, respectively. (G) Subnetwork of Cluster 1 highlighting highly connected hub targets. (H) Venn diagram showing the intersection between 18 hub targets from Cluster 1 and 484 ferroptosis-associated genes from FerrDb. The red box highlights the four final ferroptosis-associated core targets: NQO1, NOX4, NOX1, and LCN2. Molecular Complex Detection (MCODE) analysis was applied to the PPI network generated from the 66 overlapping genes and identified three densely connected clusters (Figure 3F). Cluster 1 had the highest MCODE score of 10.235, indicating the greatest topological density among the identified clusters. The interaction network of Cluster 1 was further visualized to illustrate the relationships among its constituent targets (Figure 3G). Given the potential relevance of ferroptosis to SALI, the 18 genes represented in Cluster 1 were intersected with 484 ferroptosis-related genes retrieved from the FerrDb database. This analysis identified four shared genes—NQO1, NOX4, NOX1, and LCN2 (Figure 3H). These genes were subsequently prioritized as ferroptosis-associated candidate targets potentially relevant to the effects of KS in SALI. Molecular Docking Analysis of KS Constituents and Ferroptosis-Associated Candidate Targets Based on the preceding computational analyses, molecular docking was performed between the 25 candidate bioactive constituents of KS and four ferroptosis-associated targets: NQO1, NOX4, NOX1, and LCN2. The resulting docking-score matrix was visualized as a heatmap (Figure S4A). Within the applied docking framework, most constituents exhibited more favorable predicted docking scores for NQO1, NOX4, and NOX1 than for LCN2. The complete docking-score rankings of the 25 KS constituents against the four targets are provided in Table S2. Ranking based on the mean predicted docking score across the four targets indicated that matrine had the most favorable overall score among the 25 constituents evaluated. Matrine was therefore selected for further binding-pose analysis and experimental validation. Its predicted binding poses with NQO1, NOX4, NOX1, and LCN2 were visualized using PyMOL version 2.3.0 (Figure S4B–E). Within the predicted NQO1 binding pocket, matrine formed three hydrogen bonds with TYR-128, TYR-155, and HIS-161, together with a hydrophobic interaction involving TRP-105 (Figure S4B). In the predicted matrine–NOX4 complex, hydrophobic contacts were observed with PHE-354, VAL-374, ILE-433, and PHE-577 (Figure S4C). Matrine was predicted to interact with NOX1 primarily through hydrophobic contacts involving LEU-68, VAL-71, HIS-208, and PHE-211 (Figure S4D). In contrast, the predicted matrine–LCN2 complex showed fewer contacts, involving TYR-52, HIS-77, and LYS-79 (Figure S4E). To compare the predicted binding strengths of the matrine–target complexes, the predicted docking energy (ΔG), Ki, and pKi were calculated (Table 2). Among the four targets, matrine exhibited the strongest binding affinity toward NQO1 (ΔG = −9.44 ± 0.10 kcal/mol; Ki = 0.12 ± 0.02 μM; pKi = 6.92 ± 0.07), followed by NOX4 and NOX1. In contrast, binding to LCN2 was substantially weaker (ΔG = –7.10 ± 0.64 kcal/mol; Ki = 8.99 ± 6.48 μM; pKi = 5.21 ± 0.47). Overall, these results implicate NQO1 as a potential target of matrine in SALI.Table 2Predicted Molecular Docking Parameters (ΔG, Ki, and pKi) for Matrine Against Four Core Targets (Mean ± SD, n = 5)Final Core TargetΔG (kcal/mol)Ki (μM)pKiNQO1−9.44 ± 0.100.12 ± 0.026.92 ± 0.07NOX4−8.39 ± 0.290.78 ± 0.386.15 ± 0.21NOX1−8.12 ± 0.221.17 ± 0.375.95 ± 0.16LCN2−7.10 ± 0.648.99 ± 6.485.21 ± 0.47Notes: ΔG denotes the predicted docking energy (kcal/mol). Ki denotes the predicted inhibition constant (μM), calculated from ΔG at T = 298 K using the equations described in the Methods. pKi was calculated using Ki expressed in molar units. Lower Ki values represent more favorable predicted binding. Data are presented as the mean ± SD from five independent docking simulations. \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}${K_{\mathrm{i}}} = {\mathrm{exp}}\left({\Delta{\mathrm{G}}/RT} \right)$\end{document}\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$p{K_{\mathrm{i}}} = - log10\left({{K_{\mathrm{i}}}} \right)$\end{document} Table 2Predicted Molecular Docking Parameters (ΔG, Ki, and pKi) for Matrine Against Four Core Targets (Mean ± SD, n = 5)Final Core TargetΔG (kcal/mol)Ki (μM)pKiNQO1−9.44 ± 0.100.12 ± 0.026.92 ± 0.07NOX4−8.39 ± 0.290.78 ± 0.386.15 ± 0.21NOX1−8.12 ± 0.221.17 ± 0.375.95 ± 0.16LCN2−7.10 ± 0.648.99 ± 6.485.21 ± 0.47Notes: ΔG denotes the predicted docking energy (kcal/mol). Ki denotes the predicted inhibition constant (μM), calculated from ΔG at T = 298 K using the equations described in the Methods. pKi was calculated using Ki expressed in molar units. Lower Ki values represent more favorable predicted binding. Data are presented as the mean ± SD from five independent docking simulations. \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}${K_{\mathrm{i}}} = {\mathrm{exp}}\left({\Delta{\mathrm{G}}/RT} \right)$\end{document}\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$p{K_{\mathrm{i}}} = - log10\left({{K_{\mathrm{i}}}} \right)$\end{document} Predicted Molecular Docking Parameters (ΔG, Ki, and pKi) for Matrine Against Four Core Targets (Mean ± SD, n = 5) Notes: ΔG denotes the predicted docking energy (kcal/mol). Ki denotes the predicted inhibition constant (μM), calculated from ΔG at T = 298 K using the equations described in the Methods. pKi was calculated using Ki expressed in molar units. Lower Ki values represent more favorable predicted binding. Data are presented as the mean ± SD from five independent docking simulations. \documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}${K_{\mathrm{i}}} = {\mathrm{exp}}\left({\Delta{\mathrm{G}}/RT} \right)$\end{document}\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$p{K_{\mathrm{i}}} = - log10\left({{K_{\mathrm{i}}}} \right)$\end{document} Molecular Dynamics Simulations Support Stable Matrine–NQO1 Binding To evaluate the atomic-level stability and interaction energetics of matrine binding to NQO1 (Figure S5Ai), 100-ns molecular dynamics simulations were conducted for both the matrine–NQO1 complex and the apo-NQO1 system. The RMSD trajectories indicated that both systems remained structurally stable throughout the simulations, with fluctuations confined within 0.1 nm (Figure S5Aii). Compared with the apo protein, the matrine–NQO1 complex exhibited a modestly higher RMSD, consistent with minor ligand-associated conformational adjustments. The RMSF analysis revealed comparable residue-level mobility between the two systems (Figure S5Aiii), with no substantial differences, indicating that matrine binding did not significantly affect the local flexibility of NQO1 residues. The Rg remained stable at approximately 2.3 nm in both systems (Figure S5Aiv), supporting the preservation of protein compactness and overall architecture. Hydrogen-bond analysis showed that up to three hydrogen bonds were frequently formed between matrine and NQO1 during the trajectory, although transient loss of hydrogen bonding was also observed (Figure S5Av), indicating stable ligand–protein interactions. Similarly, the SASA profiles of the two systems were nearly identical and fluctuated around 240 nm2 (Figure S5Avi), further suggesting that ligand binding did not substantially alter the solvent exposure of NQO1. Free-energy landscape (FEL) analysis showed a single, tightly clustered low-energy basin for the apo system (Figure S5B), indicating a stable and conformationally homogeneous state. In contrast, the matrine–NQO1 complex exhibited a moderately broader energy basin with a more diffuse distribution (Figure S5C), which may reflect a slight increase in conformational flexibility following ligand binding. Nevertheless, the predominant energy minimum corresponded to a stable conformational state. The binding free energy calculated using MM/GBSA was −43.43 kcal/mol (Figure S5D), indicating energetically favorable binding. Energy decomposition analysis highlighted GLN-104, TRP-105, TYR-155, and GLY-149 (chain B) as major contributors to matrine binding, with individual energy contributions ranging from −1.88 to −2.61 kcal/mol (Figure S5E), underscoring their roles in stabilizing the complex. In summary, the simulations supported the stability of the matrine–NQO1 complex and provided a structural basis for the subsequent target-engagement and pharmacological loss-of-function experiments. Matrine Engages NQO1 and Increases Its Thermal Stability Building on molecular dynamics simulations showing a stable interaction between matrine and NQO1 (Figure S5), we next evaluated this interaction using biophysical and cellular assays (Figure 4). The chemical structure of matrine is shown in Figure 4A. Consistent with the predicted binding mode, molecular dynamics simulations suggested that matrine remained stably positioned within an NQO1 binding pocket (Figure 4B). We then quantified binding by SPR. The sensorgrams showed that matrine bound to immobilized NQO1 in a concentration-dependent manner (Figure 4C), and kinetic analysis yielded an estimated dissociation constant (KD) of about 1.8 μM (Figure 4D), supporting a moderate, detectable interaction in the micromolar range. To assess whether matrine affects NQO1 stability in cells, we performed CETSA. Immunoblotting showed higher levels of soluble NQO1 in matrine-treated samples than in PBS controls at elevated temperatures (Figure 4E). Quantification further demonstrated a rightward shift in the thermal denaturation profile of NQO1 in the matrine group (Figure 4F). Two-way repeated-measures ANOVA showed a significant interaction between treatment and temperature (P < 0.001), indicating that matrine alters the thermal stability profile of NQO1 in cells. Figure 4Matrine binds to NQO1 and increases its thermal stability. (A) Chemical structure of matrine. (B) Superimposed binding conformations of matrine within NQO1 extracted at 0, 25, 50, 75, and 100 ns, supporting the temporal stability of the matrine–NQO1 complex. (C and D) SPR analysis showing concentration-dependent binding of matrine to immobilized NQO1. (E and F) CETSA showing increased thermal stability of NQO1 in matrine-treated cells compared with PBS-treated control cells. Data are presented as the mean ± SD (n = 5).Image A depicts the chemical structure of Matrine (C15H24N2O). Image B shows a protein structure with a small molecule in its binding pocket. Image C presents a sensorgram plot with time (0-300 seconds) on the x-axis and relative response (RU) on the y-axis (-20 to 60). Concentrations range from 0.16 to 10.00 micro-molar. Curves peak between 80-100 seconds and decay by 300 seconds. Image D illustrates a binding curve with concentration (M) on the x-axis (0 to 1x10 superscript -5) and relative response (RU) on the y-axis (0 to 60). Points rise to about 50 RU near 1x10 superscript -5, with K_D = 1.8 micro-molar. Image E shows immunoblot rows labeled PBS and MAT, with a temperature scale (37-72 degrees C) and a 31kDa label. Image F features a line plot with temperature (37-72 degrees C) on the x-axis and relative band intensity (0.0 to 1.2) on the y-axis. PBS and MAT values decrease with increasing temperature, with higher relative band intensity in the MAT group at elevated temperatures.Mixed figure with a chemical structure, a protein binding view and three plots of matrine and NQO1. Matrine binds to NQO1 and increases its thermal stability. (A) Chemical structure of matrine. (B) Superimposed binding conformations of matrine within NQO1 extracted at 0, 25, 50, 75, and 100 ns, supporting the temporal stability of the matrine–NQO1 complex. (C and D) SPR analysis showing concentration-dependent binding of matrine to immobilized NQO1. (E and F) CETSA showing increased thermal stability of NQO1 in matrine-treated cells compared with PBS-treated control cells. Data are presented as the mean ± SD (n = 5). Matrine Alleviates SALI and Attenuates Pulmonary Inflammation in CLP-Induced Septic Mice In the CLP model of sepsis, matrine treatment at 50 and 100 mg/kg improved survival compared with that in the CLP group, with the 100 mg/kg dose producing the greatest benefit and an effect approaching that of dexamethasone (DEX) (Figure 5A). Matrine further attenuated pulmonary edema and protein leakage, as evidenced by reductions in the lung wet-to-dry weight ratio and total protein concentration in BALF. Compared with the 50 mg/kg dose, the 100 mg/kg dose produced more consistent improvements in these parameters (Figure 5B and C). Histopathological examination showed that matrine alleviated typical SALI-associated changes, including alveolar wall thickening, interstitial edema, hemorrhage, collagen deposition, and disruption of alveolar architecture (Figure 5F). Consistently, lung injury scores and collagen deposition were significantly lower in CLP mice treated with 50 or 100 mg/kg matrine than in untreated CLP mice, with the higher dose showing the greatest overall efficacy. Consistently, lung injury scores were significantly reduced by both 50 and 100 mg/kg matrine, whereas collagen deposition was significantly reduced by 100 mg/kg matrine but not by 50 mg/kg matrine (Figure 5D and E). On this basis, 100 mg/kg matrine (MAT-H) was selected for all subsequent in vivo experiments. Figure 5Matrine improves survival and alleviates lung injury in mice with CLP-induced sepsis. (A) Kaplan–Meier survival curves showing that matrine treatment improved the 7-day survival of septic mice (Log rank test; n = 12). (B) Total protein concentration in BALF (n = 5). (C) Lung wet-to-dry (W/D) weight ratio at 24 h after CLP (n = 5). (D) Lung injury scores based on histopathological evaluation (n = 5). (E) Quantification of collagen-positive areas in lung tissues following Masson’s trichrome staining using ImageJ version 1.54 (n = 5). (F) Representative lung histological sections: H&E (upper) and Masson’s trichrome (lower). Data are presented as the mean ± SD. ns, not significant; *P < 0.05, **P < 0.01, and ***P < 0.001.A Kaplan–Meier survival curve shows improved survival in septic mice treated with matrine (MAT-H and MAT-L) and dexamethasone (DEX) compared to CLP alone. A bar graph displays BALF protein concentration, with lower levels in treated groups. Violin plots illustrate lung wet-to-dry (W/D) weight ratio and lung injury scores, both reduced in treated groups. Another bar graph shows collagen-positive area, with significant differences among groups. Histological sections stained with H&E and Masson′s trichrome reveal lung tissue changes across different treatments, highlighting reduced injury and collagen deposition in matrine-treated groups.Graphs and histology images show matrine′s effects on CLP-induced sepsis in mice. Matrine improves survival and alleviates lung injury in mice with CLP-induced sepsis. (A) Kaplan–Meier survival curves showing that matrine treatment improved the 7-day survival of septic mice (Log rank test; n = 12). (B) Total protein concentration in BALF (n = 5). (C) Lung wet-to-dry (W/D) weight ratio at 24 h after CLP (n = 5). (D) Lung injury scores based on histopathological evaluation (n = 5). (E) Quantification of collagen-positive areas in lung tissues following Masson’s trichrome staining using ImageJ version 1.54 (n = 5). (F) Representative lung histological sections: H&E (upper) and Masson’s trichrome (lower). Data are presented as the mean ± SD. ns, not significant; *P < 0.05, **P < 0.01, and ***P < 0.001. To further assess pulmonary macrophage accumulation, immunohistochemistry (IHC) for the macrophage marker F4/80 was performed. Matrine treatment substantially reduced pulmonary macrophage accumulation compared with that in the CLP group (Figure 6A). In parallel, matrine significantly reduced the BALF concentrations and pulmonary mRNA expression levels of TNF-α, IL-1β, and IL-6 (Figure 6B, C, E, F, H and I). CLP also markedly activated NF-κB signaling in the lung, as shown by increased phospho-NF-κB p65 immunostaining and protein levels. In contrast, matrine treatment significantly reduced NF-κB p65 phosphorylation, as consistently demonstrated by immunohistochemistry, immunoblotting, and immunofluorescence analyses (Figure 6D, G, J–L). Collectively, these findings indicate that matrine ameliorated SALI and attenuated macrophage-associated pulmonary inflammation. Figure 6Matrine reduces pulmonary macrophage accumulation, inflammatory cytokine production, and NF-κB activation in mice with CLP-induced sepsis. (A) Representative immunohistochemical staining of F4/80+ macrophages in lung tissues. (B) Relative TNF-α level in BALF, measured by ELISA. (C) Relative IL-1β level in BALF, measured by ELISA. (D) Representative immunohistochemical staining of phosphorylated NF-κB p65 in lung tissues. (E) Relative IL-6 level in BALF, measured by ELISA. (F) TNF-α mRNA expression in lung tissues. (G) Immunoblot analysis of phosphorylated and total NF-κB p65 in lung tissues. (H) IL-1β mRNA expression in lung tissues. (I) IL-6 mRNA expression in lung tissues. (J) Representative immunofluorescence staining of phosphorylated NF-κB p65 in lung sections. (K) Quantification of the phosphorylated NF-κB p65/total NF-κB p65 ratio. (L) Quantification of phosphorylated NF-κB p65 fluorescence intensity. Data are presented as the mean ± SD (n = 5). **P < 0.01 and ***P < 0.001.A composite figure of 12 panels labeled A through L presents lung tissue data across four conditions: Sham, CLP left parenthesis cecal ligation and puncture right parenthesis, Sham plus MAT-H and CLP plus MAT-H. CLP groups show elevated macrophage accumulation and inflammatory markers, while MAT-H treatment reduces these elevations. Panel A shows immunohistochemical staining of F4/80 macrophages, with increased positivity in CLP and reduced staining in CLP plus MAT-H. Panel B is a bar graph of BALF left parenthesis bronchoalveolar lavage fluid right parenthesis TNF-alpha levels in fold change; CLP reaches approximately 10, reduced to approximately 4 in CLP plus MAT-H, with three asterisk markers indicating less than 0.001. Panel C shows BALF IL-1 beta in fold change with similar trend. Panel D shows immunohistochemical staining of phosphorylated NF-kappa B p65, elevated in CLP and reduced with MAT-H. Panels E and F show BALF IL-6 and pulmonary TNF-alpha mRNA fold change, respectively, both elevated in CLP and attenuated by MAT-H. Panel G shows an immunoblot of phosphorylated NF-kappa B at 65 kilodalton, total NF-kappa B at 65 kilodalton and beta-ACTIN at 42 kilodalton. Panels H and I show IL-1 beta and IL-6 mRNA fold change, with CLP reaching approximately 30 to 35 and reduced in CLP plus MAT-H. Panel J shows immunofluorescence of phosphorylated NF-kappa B p65 with DAPI and merged channels. Panels K and L quantify phosphorylated NF-kappa B p65 over total NF-kappa B p65 ratio and relative fluorescence intensity, both elevated in CLP and reduced with MAT-H. Statistical comparisons between CLP and CLP plus MAT-H are marked with two asterisks for less than 0.01 and three asterisks for less than 0.001.12-panel figure: lung tissue data via immunohistochemistry, charts, blot, and fluorescence across Sham, CLP, Sham + MAT-H, and CLP + MAT-H groups. Matrine reduces pulmonary macrophage accumulation, inflammatory cytokine production, and NF-κB activation in mice with CLP-induced sepsis. (A) Representative immunohistochemical staining of F4/80+ macrophages in lung tissues. (B) Relative TNF-α level in BALF, measured by ELISA. (C) Relative IL-1β level in BALF, measured by ELISA. (D) Representative immunohistochemical staining of phosphorylated NF-κB p65 in lung tissues. (E) Relative IL-6 level in BALF, measured by ELISA. (F) TNF-α mRNA expression in lung tissues. (G) Immunoblot analysis of phosphorylated and total NF-κB p65 in lung tissues. (H) IL-1β mRNA expression in lung tissues. (I) IL-6 mRNA expression in lung tissues. (J) Representative immunofluorescence staining of phosphorylated NF-κB p65 in lung sections. (K) Quantification of the phosphorylated NF-κB p65/total NF-κB p65 ratio. (L) Quantification of phosphorylated NF-κB p65 fluorescence intensity. Data are presented as the mean ± SD (n = 5). **P < 0.01 and ***P < 0.001. Matrine Restores NQO1/SLC7A11/GPX4-Associated Anti-Ferroptotic Defenses in CLP-Induced Septic Mice Guided by the ferroptosis-associated transcriptional signatures identified in macrophages within the CD45-enriched pulmonary immune-cell compartment, we investigated whether matrine modulated anti-ferroptotic defenses in the lungs of CLP-challenged mice, with a particular focus on NQO1, SLC7A11, and GPX4. In the lung tissues of CLP-induced septic mice, GSH levels were markedly reduced, whereas MDA and Fe2+ levels were increased. Matrine treatment partially reversed these alterations, increasing GSH and decreasing MDA and Fe2+ levels (Figure 7A–C). At the protein level, CLP reduced the expression of NQO1 and the anti-ferroptotic proteins SLC7A11 and GPX4, whereas matrine treatment increased their expression relative to that in untreated CLP mice (Figure 7D–F and I). Conversely, the expression of the pro-ferroptotic marker ACSL4 was increased following CLP and reduced after matrine treatment (Figure 7G and I). IHC analysis further revealed diminished NQO1 staining in the lungs of septic mice, which was partially restored by matrine administration (Figure 7H). Consistently, immunofluorescence analysis revealed reduced NQO1 fluorescence intensity following CLP, with an increase observed in the matrine-treated group (Figure 7J and K). Figure 7Matrine restores NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses in mice with CLP-induced sepsis. (A–C) GSH, MDA, and Fe2+ levels in lung tissues. (D–G and I) Immunoblot analysis and densitometric quantification of NQO1, SLC7A11, GPX4, and ACSL4 expression in lung tissues. (H) Representative IHC staining of NQO1 in lung sections. (J and K) Representative immunofluorescence staining and quantification of NQO1 fluorescence intensity in lung tissues. Data are presented as the mean ± SD (n = 5). **P < 0.01 and ***P < 0.001.The image A showing a bar chart of GSH level, y-axis, Fold Change, from 0.0 to 1.2 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP lower than Sham and CLP plus MAT-H higher than CLP. A bracket above shows asterisk. The image B showing a bar chart of MDA level, y-axis, Fold Change, from 0 to 5 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP higher than Sham and CLP plus MAT-H lower than CLP. A bracket above shows asterisk. The image C showing a bar chart of Fe superscript 2 plus level, y-axis, Fold Change, from 0 to 3 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP higher than Sham and CLP plus MAT-H lower than CLP. A bracket above shows asterisk. The image D showing a bar chart of NQO1 over beta-ACTIN, y-axis from 0.0 to 1.5 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP lower than Sham and CLP plus MAT-H higher than CLP. Brackets show asterisk. The image E showing a bar chart of GPX4 over beta-ACTIN, y-axis from 0.0 to 1.5 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP lower than Sham and CLP plus MAT-H higher than CLP. Brackets show asterisks and asterisk. The image F showing a bar chart of SLC7A11 over beta-ACTIN, y-axis from 0.0 to 1.5 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP lower than Sham and CLP plus MAT-H higher than CLP. Brackets show asterisk and asterisk. The image G showing a bar chart of ACSL4 over beta-ACTIN, y-axis from 0 to 4 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP higher than Sham and CLP plus MAT-H lower than CLP. Brackets show asterisk. The image H showing IHC with label NQO1 and IHC, arranged by group, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H, with zoomed in insets and a scale bar labeled 100 micrometer. Staining appears reduced in CLP compared with Sham and increased in CLP plus MAT-H compared with CLP. The image I showing an immunoblot with lanes labeled Sham, CLP, Sham plus MAT-H, CLP plus MAT-H and rows labeled NQO1 31 kDa, GPX4 20 kDa, SLC7A11 55 kDa, ACSL4 79 kDa, beta-ACTIN 42 kDa. Band intensity appears lower for NQO1, GPX4 and SLC7A11 in CLP than Sham, higher in CLP plus MAT-H than CLP and ACSL4 appears higher in CLP than Sham and lower in CLP plus MAT-H than CLP. The image J showing immunofluorescence rows labeled NQO1, DAPI and Merge, across columns labeled Sham, CLP, Sham plus MAT-H, CLP plus MAT-H, with a scale bar labeled 50 micrometer. NQO1 signal appears reduced in CLP compared with Sham and increased in CLP plus MAT-H compared with CLP. The image K showing a bar chart of Relative fluorescence of NQO1, y-axis from 0.0 to 1.2 and x-axis groups, Sham, CLP, Sham plus MAT-H, CLP plus MAT-H. Bars show CLP lower than Sham and CLP plus MAT-H higher than CLP. A bracket above shows asterisk. A note on the figure reads, Data are presented as the mean plus or minus SD (n equals 5). Two asterisks indicate P less than 0.01 and three asterisks indicate P less than 0.001.A multi-panel scientific figure shows matrine reversing CLP-related lung changes in mice. Matrine restores NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses in mice with CLP-induced sepsis. (A–C) GSH, MDA, and Fe2+ levels in lung tissues. (D–G and I) Immunoblot analysis and densitometric quantification of NQO1, SLC7A11, GPX4, and ACSL4 expression in lung tissues. (H) Representative IHC staining of NQO1 in lung sections. (J and K) Representative immunofluorescence staining and quantification of NQO1 fluorescence intensity in lung tissues. Data are presented as the mean ± SD (n = 5). **P < 0.01 and ***P < 0.001. Overall, these in vivo findings were consistent with the preceding target-engagement evidence and demonstrated that matrine restored NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses, suppressed ACSL4 upregulation, and attenuated ferroptosis-associated oxidative stress in the lungs of CLP-induced septic mice. Matrine Suppresses LPS-Induced Inflammatory Activation and Restores NQO1/SLC7A11/GPX4-Associated Anti-Ferroptotic Defenses in MH-S Cells Alveolar macrophages play a crucial role in SALI. Consistent with the increased pulmonary macrophage accumulation observed in vivo (Figure 6A), we conducted in vitro experiments using MH-S cells to investigate the protective effects of matrine. The CCK-8 assay showed that matrine at concentrations up to 400 μM did not significantly reduce cell viability, whereas 800 μM matrine caused a significant decrease (Figure 8A). Therefore, 400 μM matrine was selected for subsequent experiments. LPS stimulation (1 μg/mL) reduced MH-S cell viability, which was partially restored by matrine pretreatment (Figure 8B), supporting a cytoprotective effect under inflammatory conditions. Furthermore, matrine attenuated the LPS-induced increases in TNF-α, IL-1β, and IL-6 protein levels (Figure 8C–E). In parallel, LPS increased NF-κB p65 phosphorylation, whereas matrine reduced phospho-NF-κB p65 levels without appreciably altering total NF-κB p65 expression (Figure 8F and G). Figure 8Matrine attenuates LPS-induced inflammatory activation and NF-κB p65 phosphorylation in MH-S cells. (A) MH-S cell viability was assessed using a CCK-8 assay after treatment with increasing concentrations of matrine (0–800 μM) for 24 h; 400 μM was selected for subsequent experiments. (B) LPS (1 μg/mL) significantly reduced MH-S cell viability, whereas pretreatment with 400 μM matrine partially restored cell viability. (C–E) ELISA showing that matrine attenuated LPS-induced TNF-α, IL-1β, and IL-6 production. (F and G) Immunoblot analysis and quantification of phosphorylated and total NF-κB p65 (p-NF-κB/NF-κB) in MH-S cells. Data are presented as the mean ± SD (n = 5). ns, not significant; **P < 0.01 and ***P < 0.001.Image A: Bar chart of cell viability (%) vs matrine concentration (microM). Bars near 100% at 0, 100, 200, 400 microM; ~85% at 800 microM. Significance: ns, **. Image B: Cell viability (%) vs conditions (Control, LPS, Control+MAT, LPS+MAT). Bars ~100%, ~55%, ~100%, ~80%. Significance: *** Control vs LPS, *** Control+MAT vs LPS+MAT. Image C: TNF alpha fold change vs conditions. Bars ~1, ~6.5, ~1, ~4. Significance: *** Control vs LPS, ** LPS vs LPS+MAT. Image D: IL-1 beta fold change vs conditions. Bars ~1, ~6.5, ~1, ~4. Significance: *** Control vs LPS, *** LPS vs LPS+MAT. Image E: IL-6 fold change vs conditions. Bars ~1, ~7, ~1, ~3. Significance: *** Control vs LPS, *** LPS vs LPS+MAT. Image F: p NF kappaB/NF kappaB ratio vs conditions. Bars ~1.0, ~1.3, ~0.9, ~1.0. Significance: *** Control vs LPS, ** LPS vs LPS+MAT. Image G: Immunoblot with lanes Control, LPS, Control+MAT, LPS+MAT. Rows: p NF kappaB (65 kDa), NF kappaB (65 kDa), beta ACTIN (42 kDa).A set of bar charts and an immunoblot showing MH-S cell viability, cytokines and NF-kappaB p65. Matrine attenuates LPS-induced inflammatory activation and NF-κB p65 phosphorylation in MH-S cells. (A) MH-S cell viability was assessed using a CCK-8 assay after treatment with increasing concentrations of matrine (0–800 μM) for 24 h; 400 μM was selected for subsequent experiments. (B) LPS (1 μg/mL) significantly reduced MH-S cell viability, whereas pretreatment with 400 μM matrine partially restored cell viability. (C–E) ELISA showing that matrine attenuated LPS-induced TNF-α, IL-1β, and IL-6 production. (F and G) Immunoblot analysis and quantification of phosphorylated and total NF-κB p65 (p-NF-κB/NF-κB) in MH-S cells. Data are presented as the mean ± SD (n = 5). ns, not significant; **P < 0.01 and ***P < 0.001. We next evaluated whether matrine attenuated ferroptosis-associated oxidative injury. Fluorescence-based assays showed that LPS increased intracellular ROS accumulation, induced mitochondrial membrane depolarization, and enhanced lipid peroxidation, as indicated by increased DCF fluorescence, a shift in JC-1 fluorescence from red to green, and increased BODIPY-C11 oxidation, respectively. Matrine attenuated ROS accumulation (Figure 9A and B), preserved the mitochondrial membrane potential (ΔΨm) (Figure 9C and D), and reduced lipid peroxidation (Figure 9E and F), supporting its antioxidant effects and preservation of mitochondrial function. We further measured intracellular GSH, MDA, and Fe2+ levels to assess ferroptosis-associated biochemical alterations. LPS stimulation depleted GSH and increased MDA and Fe2+ levels, whereas matrine increased GSH and reduced MDA and Fe2+ levels (Figure 10A–C). Immunoblotting showed that LPS reduced the expression of NQO1, GPX4, and SLC7A11 while increasing ACSL4 expression (Figure 10D–H). In contrast, matrine treatment restored NQO1, GPX4, and SLC7A11 expression and suppressed ACSL4 upregulation in LPS-stimulated MH-S cells. Immunofluorescence analysis further revealed that LPS exposure reduced NQO1 fluorescence intensity, which was partially restored by matrine treatment (Figure 10I–J). Collectively, these findings suggest that matrine attenuated LPS-induced inflammatory activation and ferroptosis-associated oxidative stress in MH-S cells, accompanied by restoration of NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses. Figure 9Matrine attenuates LPS-induced ROS accumulation, mitochondrial membrane depolarization, and lipid peroxidation in MH-S cells. (A and B) Intracellular ROS levels were assessed using a DCFH-DA fluorescence assay; matrine treatment significantly reduced LPS-induced ROS accumulation. (C and D) Mitochondrial membrane potential (ΔΨm) was assessed using JC-1 staining. LPS exposure induced mitochondrial depolarization, as indicated by a shift from red to green fluorescence, and this effect was attenuated by matrine. (E and F) Lipid peroxidation was assessed using BODIPY-C11 staining. Data are presented as the mean ± SD (n = 5). *P < 0.05, **P < 0.01, and ***P < 0.001.The image A showing a 3 by 4 grid of fluorescence micrographs labeled by columns, Control, LPS, Control plus MAT and LPS plus MAT and by rows, ROS, Hoechst 33342 and Merge. ROS row shows sparse puncta in Control, many puncta in LPS, sparse puncta in Control plus MAT and moderate puncta in LPS plus MAT. Hoechst 33342 row shows many nuclei dots in all four conditions. Merge row overlays the two signals. A scale bar labeled 50 micrometer appears at lower right. The image B showing a bar chart of Relative Fluorescence of ROS. X-axis categories: Control, LPS, Control plus MAT, LPS plus MAT. Y-axis ranges 0 to 3 with ticks at 0, 1, 2, 3. Bars are approximately 1.0, 2.4, 1.1 and 1.8, with five overlaid points per bar. Significance marks show three asterisks between Control and LPS and one asterisk between LPS and LPS plus MAT. The image C showing a 3 by 4 grid of JC-1 staining micrographs with columns, Control, LPS, Control plus MAT and LPS plus MAT and rows, JC-1 Aggregate, JC-1 Monomer and Merge. Aggregate row shows many puncta in Control, sparse puncta in LPS, many puncta in Control plus MAT and many puncta in LPS plus MAT. Monomer row shows sparse puncta in Control, many puncta in LPS, sparse puncta in Control plus MAT and sparse to moderate puncta in LPS plus MAT. Merge row overlays both signals. A scale bar labeled 50 micrometer appears at lower right. The image D showing a bar chart of Relative Fluorescence of JC-1 with parenthetical text, Aggregate over Monomer. X-axis categories: Control, LPS, Control plus MAT, LPS plus MAT. Y-axis ranges 0 to 2.0 with ticks at 0, 0.5, 1.0, 1.5, 2.0. Bars are approximately 1.0, 0.2, 1.0 and 0.8, with five overlaid points per bar. Significance marks show three asterisks between Control and LPS and two asterisks between LPS and LPS plus MAT. The image E showing a 3 by 4 grid of BODIPY-C11 micrographs with columns, Control, LPS, Control plus MAT and LPS plus MAT and rows, Unoxidized Bodipy, Oxidized Bodipy and Merge. Unoxidized Bodipy row shows many puncta in Control, sparse puncta in LPS, many puncta in Control plus MAT and moderate puncta in LPS plus MAT. Oxidized Bodipy row shows sparse puncta in Control, many puncta in LPS, sparse puncta in Control plus MAT and sparse puncta in LPS plus MAT. Merge row overlays both signals. A scale bar labeled 50 micrometer appears at lower right. The image F showing a bar chart of Relative Fluorescence of Bodipy with parenthetical text, Unoxidized over Oxidized. X-axis categories: Control, LPS, Control plus MAT, LPS plus MAT. Y-axis ranges 0 to 1.5 with ticks at 0, 0.5, 1.0, 1.5. Bars are approximately 1.0, 0.2, 0.9 and 0.55, with five overlaid points per bar. Significance marks show three asterisks between Control and LPS and one asterisk between LPS and LPS plus MAT.Six-panel fluorescence images and bar charts show ROS, JC-1 and BODIPY changes across treatments. Figure 10Matrine restores NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses in MH-S cells. (A–C) Intracellular GSH, MDA, and Fe2+ levels in MH-S cells. (D–H) Representative immunoblots and densitometric quantification of NQO1, SLC7A11, GPX4, and ACSL4 expression in MH-S cells. (I and J) Representative immunofluorescence staining of NQO1 and quantification of its fluorescence intensity. Data are presented as the mean ± SD (n = 5). *P < 0.05, **P < 0.01, and ***P < 0.001.The image A showing a bar chart of GSH level (fold change). X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: GSH level (fold change), scale 0 to 1.5. Bars show Control near 1.0, LPS near 0.6, Control+MAT near 0.9, LPS+MAT near 1.0, with asterisks above group comparisons. The image B showing a bar chart of MDA level (fold change). X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: MDA level (fold change), scale 0 to 6. Bars show Control near 1.0, LPS near 4.0, Control+MAT near 1.2, LPS+MAT near 2.5, with asterisks above comparisons. The image C showing a bar chart of Fe2 plus level (fold change). X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: Fe2 plus level (fold change), scale 0 to 4. Bars show Control near 1.0, LPS near 2.8 to 3.0, Control+MAT near 1.1, LPS+MAT near 1.7 to 1.8, with asterisks above comparisons. The image D showing a bar chart of NQO1 over beta-ACTIN. X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: NQO1/beta-ACTIN, scale 0 to 1.5. Bars show Control near 1.0, LPS near 0.6, Control+MAT near 1.1, LPS+MAT near 0.9 to 1.0, with asterisks above comparisons. The image E showing immunoblots with lanes labeled Control, LPS, Control+MAT, LPS+MAT. Targets and sizes: NQO1 31 kDa, GPX4 20 kDa, SLC7A11 55 kDa, ACSL4 79 kDa, beta-ACTIN 42 kDa. Band intensity appears lower for NQO1, GPX4 and SLC7A11 in LPS than Control and higher for ACSL4 in LPS than Control. The image F showing a bar chart of GPX4 over beta-ACTIN. X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: GPX4/beta-ACTIN, scale 0 to 1.5. Bars show Control near 1.0, LPS near 0.5 to 0.6, Control+MAT near 1.1, LPS+MAT near 1.0, with asterisks above comparisons. The image G showing a bar chart of SLC7A11 over beta-ACTIN. X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: SLC7A11/beta-ACTIN, scale 0 to 1.5. Bars show Control near 1.0, LPS near 0.6, Control+MAT near 1.0, LPS+MAT near 0.9, with asterisks above comparisons. The image H showing a bar chart of ACSL4 over beta-ACTIN. X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: ACSL4/beta-ACTIN, scale 0 to 2.0. Bars show Control near 1.0, LPS near 1.5 to 1.6, Control+MAT near 1.0, LPS+MAT near 1.1, with asterisks above comparisons. The image I showing immunofluorescence micrographs arranged in four columns labeled Control, LPS, Control+MAT, LPS+MAT and three rows labeled NQO1, DAPI and Merge. NQO1 signal appears as punctate staining around cells, DAPI marks nuclei and Merge overlays both signals. NQO1 staining appears reduced in LPS compared with Control and stronger in Control+MAT and LPS+MAT compared with LPS. A scale bar reads 10 micrometer. The image J showing a bar chart of Relative fluorescence of NQO1. X-axis: Control, LPS, Control+MAT, LPS+MAT. Y-axis: Relative fluorescence of NQO1, scale 0 to 1.5. Bars show Control near 1.0, LPS near 0.2 to 0.3, Control+MAT near 1.0, LPS+MAT near 0.6 to 0.7, with asterisks above comparisons. Across the bar charts and microscopy, LPS is associated with lower GSH and lower NQO1, GPX4 and SLC7A11 measures, higher MDA, higher Fe2 plus and higher ACSL4, while MAT groups show values closer to Control in multiple readouts. Asterisks are shown above selected comparisons.A multi-panel biomedical infographic on matrine effects in MH-S cells: bar charts, immunoblot, microscopy. Matrine attenuates LPS-induced ROS accumulation, mitochondrial membrane depolarization, and lipid peroxidation in MH-S cells. (A and B) Intracellular ROS levels were assessed using a DCFH-DA fluorescence assay; matrine treatment significantly reduced LPS-induced ROS accumulation. (C and D) Mitochondrial membrane potential (ΔΨm) was assessed using JC-1 staining. LPS exposure induced mitochondrial depolarization, as indicated by a shift from red to green fluorescence, and this effect was attenuated by matrine. (E and F) Lipid peroxidation was assessed using BODIPY-C11 staining. Data are presented as the mean ± SD (n = 5). *P < 0.05, **P < 0.01, and ***P < 0.001. Matrine restores NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses in MH-S cells. (A–C) Intracellular GSH, MDA, and Fe2+ levels in MH-S cells. (D–H) Representative immunoblots and densitometric quantification of NQO1, SLC7A11, GPX4, and ACSL4 expression in MH-S cells. (I and J) Representative immunofluorescence staining of NQO1 and quantification of its fluorescence intensity. Data are presented as the mean ± SD (n = 5). *P < 0.05, **P < 0.01, and ***P < 0.001. Pharmacological Inhibition of NQO1 Attenuates the Protective Effects of Matrine in LPS-Stimulated MH-S Cells To determine the functional contribution of NQO1 to matrine-mediated protection, MH-S cells were treated with the NQO1 inhibitor ES936. The concentration-screening experiment showed that ES936 at concentrations of 25–200 nM did not significantly affect basal cell viability, whereas 500 nM ES936 significantly reduced cell viability (Figure 11A). Accordingly, 100 nM ES936 was selected for subsequent experiments. Figure 11Pharmacological inhibition of NQO1 attenuates the protective effects of matrine in LPS-stimulated MH-S cells. (A) MH-S cell viability after treatment with increasing concentrations of ES936 (0–500 nM) for 24 h. (B) Cell viability in the Control, LPS, LPS + ES936, LPS + MAT, and LPS + MAT + ES936 groups. (C–E) Intracellular GSH, MDA, and Fe2+ levels. (F–L) Representative immunoblots and densitometric quantification of the phosphorylated NF-κB p65/total NF-κB p65 ratio and the expression levels of NQO1, GPX4, SLC7A11, and ACSL4 in MH-S cells. Data are presented as the mean ± SD (n = 5). ns, not significant; *P < 0.05, **P < 0.01, and ***P < 0.001.The image consists of multiple graphs and immunoblots showing the effects of various treatments on MH-S cells. A shows cell viability with ES936 concentrations from 0 to 500 nM, indicating no significant change up to 200 nM, but a decrease at 500 nM. B shows cell viability across Control, LPS, LPS + ES936, LPS + MAT and LPS + MAT + ES936 groups, with significant differences noted. C, D and E display fold changes in GSH, MDA and Fe superscript 2+ levels, respectively, across the same groups, with significant differences. F, G, H, I and J show the ratios of phosphorylated NF-kappaB p65 to total NF-kappaB p65 and expression levels of NQO1, GPX4, SLC7A11 and ACSL4, respectively, with significant differences. K presents immunoblots for p-NF-kappaB, NF-kappaB and beta-ACTIN, with molecular weights. L shows immunoblots for NQO1, GPX4, SLC7A11, ACSL4 and beta-ACTIN, with molecular weights indicated.Graphs and immunoblots show effects of treatments on MH-S cells. Pharmacological inhibition of NQO1 attenuates the protective effects of matrine in LPS-stimulated MH-S cells. (A) MH-S cell viability after treatment with increasing concentrations of ES936 (0–500 nM) for 24 h. (B) Cell viability in the Control, LPS, LPS + ES936, LPS + MAT, and LPS + MAT + ES936 groups. (C–E) Intracellular GSH, MDA, and Fe2+ levels. (F–L) Representative immunoblots and densitometric quantification of the phosphorylated NF-κB p65/total NF-κB p65 ratio and the expression levels of NQO1, GPX4, SLC7A11, and ACSL4 in MH-S cells. Data are presented as the mean ± SD (n = 5). ns, not significant; *P < 0.05, **P < 0.01, and ***P < 0.001. LPS significantly reduced cell viability, whereas matrine partially restored it. ES936 did not further reduce cell viability compared with LPS treatment alone but significantly attenuated the matrine-mediated recovery of cell viability (Figure 11B). Matrine also increased GSH levels and decreased MDA and Fe2+ levels in LPS-stimulated cells, whereas these effects were partially reversed by ES936 (Figure 11C–E). Immunoblotting showed that ES936 attenuated the matrine-mediated restoration of NQO1, GPX4, and SLC7A11 expression, partially reversed the matrine-induced reduction in ACSL4 expression, and increased the phospho-NF-κB p65/total NF-κB p65 ratio relative to that in the LPS + MAT group (Figure 11F–L). Collectively, these findings support a functional contribution of NQO1 to the anti-ferroptotic and NF-κB-suppressive effects of matrine. However, the partial reversal by ES936 suggests that additional NQO1-independent mechanisms may also contribute to matrine-mediated protection. Discussion Sepsis-induced acute lung injury (SALI) and acute respiratory distress syndrome (ARDS) remain major causes of respiratory failure and poor outcomes in critically ill patients.33 Despite advances in supportive care, the heterogeneous immune, metabolic, endothelial, and cell-death responses involved in sepsis continue to impede the development of mechanism-directed therapies.2 The pathophysiology of ARDS remains incompletely understood, and effective preventive strategies are limited; consequently, these conditions continue to pose substantial challenges in both basic and translational research. In the present study, we investigated the therapeutic potential of matrine, a bioactive alkaloid derived from Sophora flavescens,34 using a CLP-induced SALI model and obtained evidence supporting its protective effects against SALI. Matrine alleviated SALI and reduced the inflammatory burden, accompanied by attenuation of ferroptosis-associated oxidative stress and NF-κB-associated inflammatory signaling. Reanalysis of GSE273924 revealed marked remodeling of the CD45-enriched pulmonary immune-cell compartment during intratracheal Escherichia coli-induced pneumonia, with increased representation of macrophages and neutrophils and relative reductions in several adaptive immune-cell subsets. In macrophages, ferroptosis- and inflammation-associated gene signatures were enriched, suggesting a potential link between oxidative injury and inflammatory amplification. Based on these findings, we focused subsequent experimental validation on macrophages and evaluated changes in NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses and NF-κB-associated inflammatory signaling. Ferroptosis may represent a mechanistic link among oxidative stress, lipid peroxidation, and inflammatory amplification in SALI.35 SLC7A11 maintains intracellular antioxidant capacity by facilitating cystine uptake and glutathione synthesis, whereas GPX4 detoxifies lipid hydroperoxides and protects cell membranes from lipid peroxidation.36,37 In contrast, ACSL4 promotes lipid remodeling and increases cellular susceptibility to ferroptotic injury.38 Accordingly, disruption of these regulatory mechanisms may exacerbate oxidative damage and inflammatory responses during SALI. In the present study, matrine restored NQO1, SLC7A11, and GPX4 expression, increased GSH levels, and suppressed ACSL4 upregulation while reducing MDA and Fe2+ levels. Collectively, these findings suggest that matrine strengthens coordinated anti-ferroptotic defenses, thereby attenuating ferroptosis-associated oxidative injury and inflammatory amplification in SALI. To better connect the preceding scRNA-seq findings with potential therapeutic mechanisms, we integrated network pharmacology-based target prediction with bioinformatics analyses and identified NQO1 as a leading candidate for subsequent validation. Notably, ferroptosis and NF-κB signaling were among the prominently enriched pathways, consistent with their reported involvement in sepsis-related organ dysfunction.2 NQO1 was prioritized not only because of its high ranking in the computational screening but also because accumulating evidence places it at a key regulatory interface between oxidative stress and inflammatory amplification in SALI. NQO1 is a cytoprotective, flavin-dependent antioxidant enzyme involved in the regulation of oxidative stress,39–41 iron metabolism,42,43 and NF-κB signaling.44–46 Mechanistically, NQO1 catalyzes the two-electron reduction of quinones, thereby limiting redox cycling and supporting the regeneration of radical-trapping antioxidants, including reduced coenzyme Q10 and vitamin E-related quinones. These activities may strengthen antioxidant defenses, restrict the propagation of membrane lipid peroxidation, and suppress ferroptotic injury.47 Moreover, ROS and NF-κB signaling are closely interconnected: ROS can promote NF-κB activation, whereas NF-κB induces multiple inflammatory and stress-response genes, thereby establishing a potential feed-forward loop.48 Previous studies have further suggested that NQO1 may attenuate NF-κB-dependent transcriptional activity, as NQO1 silencing has been associated with increased nuclear accumulation of IKKα and NF-κB and enhanced interaction between NF-κB and the coactivator p300.49 Collectively, these lines of evidence position NQO1 as a mechanistically plausible and experimentally testable target that may link ferroptosis-associated oxidative injury to inflammatory amplification in SALI, supporting its selection for functional validation. We employed a stepwise computational and experimental workflow comprising binding-pose prediction, complex-stability assessment, biophysical binding measurements, and cellular target-engagement analysis to characterize the interaction between matrine and NQO1. Molecular docking suggested that matrine occupied the predicted NQO1 binding pocket, forming three hydrogen bonds with TYR-128, TYR-155, and HIS-161, together with a hydrophobic contact involving TRP-105. Among the candidate targets, NQO1 exhibited the most favorable docking-derived binding estimates (ΔG = −9.44 ± 0.10 kcal/mol; Ki = 0.12 ± 0.02 μM; pKi = 6.92 ± 0.07). Molecular dynamics simulations further showed a modest increase in the RMSD of the matrine–NQO1 complex relative to the apo-NQO1 system, suggesting minor ligand-associated conformational adjustments while overall structural stability was maintained. Consistent with these computational findings, SPR sensorgrams revealed concentration-dependent binding of matrine to immobilized NQO1, and kinetic analysis yielded an estimated dissociation constant (KD) of approximately 1.8 μM, supporting a direct, moderate-affinity interaction in the micromolar range. Further supporting cellular target engagement, CETSA showed that matrine treatment increased the amount of soluble NQO1 retained at elevated temperatures and shifted the thermal denaturation curve to the right, consistent with enhanced NQO1 thermal stability in cells and intracellular target engagement. We subsequently evaluated the in vivo efficacy of matrine in the CLP model of sepsis. Matrine treatment was associated with improved survival, reduced lung injury, and a lower inflammatory burden. Mechanistically, matrine treatment was accompanied by attenuation of ferroptosis-associated changes, restoration of NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses, and suppression of NF-κB-mediated inflammatory responses. Similarly, Zhang et al reported that matrine alleviated sepsis-associated myocardial injury by modulating ferroptosis-associated proteins and restoring mitochondrial homeostasis.50 Moreover, in LPS-stimulated MH-S cells, matrine preserved the mitochondrial membrane potential, reduced ROS accumulation, and decreased lipid peroxidation, further supporting its anti-ferroptotic effects at the cellular level. Collectively, the in vivo and in vitro findings support a model in which the protective effects of matrine are associated with enhanced NQO1/SLC7A11/GPX4-associated antioxidant and anti-ferroptotic defenses, together with attenuation of inflammatory responses. To move beyond evidence of target engagement and phenotypic associations, we pharmacologically inhibited NQO1 using ES936. ES936 partially attenuated the beneficial effects of matrine on cell viability, redox homeostasis, ferroptosis-associated markers, and NF-κB p65 phosphorylation, supporting a functional contribution of NQO1 to matrine-mediated protection. This finding is consistent with previous evidence suggesting that NQO1-mediated redox reactions may limit ferroptotic injury, whereas NQO1 inhibition or downregulation is associated with increased susceptibility to ferroptosis and NQO1 overexpression confers protection.51,52 An important question is how macrophage-centered regulation of ferroptosis relates to improvements in overall lung injury. In this study, the omics analyses and in vitro validation primarily identified macrophages as a major responsive immune-cell population. In LPS-stimulated MH-S cells, matrine restored NQO1, SLC7A11, and GPX4 expression, suppressed ACSL4 upregulation, preserved GSH levels, and reduced MDA and Fe2+ accumulation, ROS production, mitochondrial membrane depolarization, and lipid peroxidation. These findings suggest that matrine attenuated ferroptosis-associated oxidative injury in macrophages under inflammatory conditions. Recent intervention-based studies further support the functional relevance of macrophage ferroptosis in experimental SALI. Specifically, pharmacological or genetic modulation of Nrf2 signaling, OTUD1–AMPK/GSK3β/β-catenin signaling, and macrophage iron handling altered ferroptosis, inflammatory injury, pulmonary edema, and lung tissue damage.53–56 Nevertheless, SALI is a multicellular pathological process involving macrophages, neutrophils, alveolar epithelial cells, pulmonary endothelial cells, and other immune and stromal cell populations. Although alveolar epithelial and endothelial cells are major structural targets of lung injury, activated macrophages may act as upstream amplifiers of tissue damage by releasing TNF-α, IL-1β, IL-6, ROS, and lipid peroxidation-associated signals, thereby promoting endothelial activation, epithelial injury, inflammatory-cell recruitment, and alveolar–capillary barrier dysfunction.57,58 Thus, matrine-mediated attenuation of ferroptosis-associated oxidative stress and inflammatory activation in macrophages may improve the pulmonary inflammatory microenvironment and secondarily alleviate epithelial and endothelial barrier injury, thereby contributing to the overall amelioration of SALI. Consistent with this interpretation, our in vivo analyses showed restoration of NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses, reduced ACSL4 expression, increased GSH levels, and decreased MDA and Fe2+ levels in whole-lung tissues. These findings support the attenuation of ferroptosis-associated oxidative stress in the lungs of septic mice but do not definitively identify the specific pulmonary cell types in which ferroptotic injury was reduced. Therefore, the potential direct effects of matrine on ferroptosis in alveolar epithelial and pulmonary endothelial cells remain to be determined. Collectively, these findings provide a rationale for the further preclinical and translational evaluation of matrine. From a translational perspective, matrine is a structurally defined natural product and a single chemical entity, which facilitates reproducible quality control, enables PK/PD profiling and mechanistic investigation, and provides a practical chemical scaffold for structure–activity optimization and improvements in formulation and drug delivery.34 In addition, Sophora flavescens-derived alkaloid formulations, such as Compound Kushen Injection, which contains matrine and oxymatrine as major constituents, have gained clinical experience as adjunctive therapies in oncology. This clinical experience provides a translational precedent for the further evaluation of matrine and its potential repurposing for conditions such as SALI.59,60 The relatively high concentration of matrine used in the in vitro experiments should be interpreted with caution. In MH-S cells, 400 μM matrine was selected based on the CCK-8 assay because it was the highest tested concentration that did not significantly reduce cell viability, whereas 800 μM matrine caused a significant decrease. Thus, 400 μM matrine was used to enable mechanistic evaluation during sustained LPS stimulation rather than to directly mimic systemic plasma exposure in mice. Based on its molecular weight, 400 μM matrine corresponds to approximately 99 μg/mL, which is higher than the plasma concentrations generally reported after conventional in vivo administration. Previous pharmacokinetic studies have shown that matrine has limited oral bioavailability and undergoes rapid systemic elimination. For example, Yang et al reported an absolute oral bioavailability of 17.1 ± 5.4% in rats and substantially lower plasma concentrations after oral administration than after intravenous administration.61 Moreover, systematic reviews have indicated that matrine has a relatively short in vivo half-life and notable pharmacokinetic limitations that may restrict systemic exposure.13,14 Local tissue concentrations may also differ from circulating plasma concentrations; therefore, plasma Cmax alone may not accurately reflect drug exposure in disease-relevant tissues. These pharmacokinetic characteristics indicate that the nominal concentration used in cell culture should not be directly equated with the plasma Cmax achieved in vivo. Furthermore, in vitro culture systems do not reproduce absorption, distribution, metabolism, clearance, tissue partitioning, or multicellular immune and inflammatory interactions. Notably, previous in vitro studies of matrine have used concentrations ranging from several hundred micromolar to millimolar levels to investigate pathway regulation and antitumor mechanisms. For example, matrine concentrations of 0.25–1.25 mM have been used in colon cancer cells to evaluate apoptosis, G0/G1 cell-cycle arrest, and regulation of the Wnt/β-catenin and MEK/ERK signaling pathways.62 These studies provide experimental precedent for the use of relatively high matrine concentrations in mechanistic investigations under controlled cell-culture conditions. Accordingly, 400 μM matrine should be regarded as a mechanistic experimental condition used to assess whether matrine directly modulates MH-S cells and affects NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses and NF-κB-associated inflammatory signaling, rather than as a surrogate for clinically achievable plasma concentrations. Future studies incorporating PK/PD modeling, measurements of lung tissue exposure and unbound drug concentrations, and prolonged low-concentration exposure models are needed to better relate these in vitro findings to pharmacologically relevant in vivo exposure. Despite these encouraging findings, several limitations warrant consideration. First, the public scRNA-seq dataset and our in vivo validation experiments were based on different disease models. The scRNA-seq data in GSE273924 were derived from CD45-enriched pulmonary immune cells isolated from mice with intratracheal Escherichia coli-induced pneumonia, whereas our in vivo experiments used a CLP-induced polymicrobial sepsis model. Intratracheal E. coli instillation primarily models direct pulmonary infection and pneumonia-associated lung inflammation, whereas CLP represents systemic polymicrobial sepsis arising from an extrapulmonary abdominal infectious source and is commonly used to model indirect sepsis-associated lung injury.63,64 Therefore, GSE273924 was used as an exploratory public resource to identify immune-cell-specific inflammatory and ferroptosis-associated programs, rather than as a model-identical substitute for CLP-induced SALI. The relevance of these exploratory findings was subsequently evaluated in our CLP-induced lung injury model and in LPS-stimulated MH-S cells. Future CLP-derived pulmonary immune-cell scRNA-seq datasets would further strengthen model-specific evidence. Second, although the omics and in vitro analyses supported macrophages as a major responsive cell population, the in vivo ferroptosis-associated assessments were performed using whole-lung tissues and therefore lacked cell-type specificity. Consequently, the specific pulmonary cell types in which matrine attenuated ferroptosis-associated injury in vivo remain to be determined. Third, the mechanistic attribution to NQO1 remains incomplete. Although ES936 provided pharmacological loss-of-function evidence, NQO1 enzymatic activity and the extent and persistence of its inhibition throughout the subsequent 24-h LPS exposure were not directly measured in MH-S cells. Moreover, pharmacological inhibition alone cannot fully exclude potential off-target effects. Concurrent changes in ferroptosis-associated indices and NF-κB p65 phosphorylation also do not establish their relative contributions or causal sequence. Dexamethasone served as an anti-inflammatory and lung-protective positive control but was not intended to distinguish ferroptosis-dependent protection from inflammation-dependent protection. Therefore, future studies combining direct NQO1 activity assays, genetic Nqo1 knockdown or knockout with rescue experiments, targeted perturbation of NF-κB signaling, and ferroptosis-targeted interventions, such as ferrostatin-1 or liproxstatin-1, are needed to confirm target specificity and clarify the relationships among these mechanisms. Fourth, the generalizability and translational relevance of these findings require further evaluation. Validation in additional models of sepsis and lung injury, primary human pulmonary cells, and clinically derived human samples will be necessary to determine whether the protective effects of matrine extend beyond the experimental systems used in the present study. Pharmacokinetic, pharmacodynamic, and dose-optimization studies will also be required before the clinical translation of matrine can be considered. Finally, although molecular docking, 100-ns molecular dynamics simulations, SPR, and CETSA collectively supported target engagement between matrine and NQO1, the predicted binding mode has not been confirmed at high structural resolution. The 100-ns simulation period may not have captured slower conformational rearrangements or rare ligand-dissociation events, and the predicted key binding residues remain experimentally unverified. Longer microsecond-scale simulations or enhanced-sampling approaches,65 together with high-resolution structural methods, such as cryo-electron microscopy or X-ray crystallography,66,67 followed by site-directed mutagenesis, would help define the binding interface and validate the functional importance of the predicted residues. Conclusion Matrine protected against CLP-induced SALI in vivo and LPS-induced injury in MH-S cells in vitro. An integrated workflow incorporating network pharmacology, molecular docking, molecular dynamics simulations, SPR, and CETSA prioritized NQO1 as a leading candidate target of matrine. Pharmacological inhibition of NQO1 with ES936 partially attenuated the matrine-mediated restoration of cell viability, redox homeostasis, and anti-ferroptotic defenses, as well as the suppression of NF-κB p65 phosphorylation, further supporting a functional contribution of NQO1 to these protective effects. Collectively, these multilevel findings support a model in which matrine alleviates SALI by strengthening NQO1/SLC7A11/GPX4-associated anti-ferroptotic defenses and attenuating NF-κB-driven inflammation. Overall, matrine represents a potential therapeutic candidate for SALI and warrants further preclinical and translational evaluation, particularly regarding the contribution of NQO1-associated mechanisms to its protective effects.